Cell and Gene Therapy Supply Chain Software Market: Industry Trends and Global Forecasts to 2035: Distribution by Process Component, Type of Software, Mode of Deployment, Scale of Operation, Type of End-user and Key Geographical Regions

The global cell and gene therapy supply chain software market is estimated to grow from USD 0.27 billion in 2025, to USD 1.32 billion by 2035, at a CAGR of 15.2% during the forecast period, to 2035.

CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET: GROWTH AND TRENDS

Advanced therapies are gradually evolving the face of modern healthcare. These new regenerative and immunotherapy modalities have the potential to improve treatment outcomes by providing viable therapy solutions to patients who currently have limited or no treatment options. Given the nature of these treatment modalities, these therapies have a limited lifespan, even when shipped under temperature-controlled conditions. It becomes increasingly important to track the source of the sample from the time of its collection, current location and manufacturing processes. Following this fact, for the commercial success of such therapies, an effective manufacturing platform and a robust supply chain model are imperative. It is worth mentioning that a sustainable supply chain enables further reductions in the cost of goods and, in turn, prices of such therapies.

The supply chain for innovative therapies is complicated from the outset and given the interdependencies amongst multiple stakeholders, it becomes challenging to manage and streamline the overall process. This has reinforced the need for bespoke and integrated software solutions to help innovators manage the critical intricacies of the supply chain. These software systems have huge potential to manage a multitude of events, maintain the chain of identity and custody, and enable stakeholders to optimize the complex supply chains, while also ensuring compliance with global regulatory standards. Driven by the growing demand for cell and gene therapies and the availability of easy to integrate software solutions to manage cell and gene therapy supply chain, this market is expected to grow significantly in the foreseen future.

CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET: KEY INSIGHTS

The report delves into the current state of the cell and gene therapy supply chain software market and identifies potential growth opportunities within the industry.

Some key findings from the report include:

Presently, close to 175 cell and gene therapy supply chain software solutions are available in the market; of these, 22% are laboratory information management systems.

Over 20% of the cell and gene therapy supply chain software solutions can be deployed both on-premises and over the cloud, offering flexibility as well as contact-less options for the end-users.
The current market landscape of cell and gene therapy supply chain software providers is fragmented, featuring the presence of both new entrants and established players; majority of these players are based in the US.
The growing interest in this domain is evident from the rise in partnership activity; in fact, 40 partnership deals related to cell and gene therapy supply chain software were inked in 2023.
Several investors, having realized the opportunities associated within supply chain management software domain, have invested USD 3 billion across various funding rounds in the past 10 years.
Driven by the increasing pace of innovation and partnership activity, the market for cell and gene therapy supply chain software is poised to witness steady growth in the foreseeable future.
The cell and gene therapy supply chain software market is anticipated to grow at a CAGR of 15.2%, till 2035; North America is expected to capture the majority share (over 45%) of the market by 2035.

Market opportunities in the cell and gene therapy supply chain software market has been distributed across the following segments:

Process Component

Sample Collection and Processing Component
Manufacturing Component
Logistics Component
Patient Identification and Treatment Follow-up Component

Type of Software

Enterprise Manufacturing System (EMS)
Laboratory Information Management System (LIMS)
Inventory Management System (IMS)
Cell Orchestration Platform (COP)
Quality Management System (QMS)
Logistics Management System (LMS)
Patient Management System (PMS)

Mode of Deployment

On-premises Deployment
Cloud-based Deployment

Type of End-User

Pharmaceutical Companies
Cell Therapy Labs
Hospitals / Medical Centers
Research Institutes / Biobanks

Scale of Operation

Clinical Scale
Commercial Scale

Key Geographical Regions

North America
Europe
Asia-Pacific
Rest of the World

CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET: KEY SEGMENTS

Manufacturing of Cell and Gene Therapies Occupy the Largest Share of the Overall Market

Based on the process components, the market is segmented into sample collection and processing, manufacturing, logistics, and patient identification and treatment follow-up. At present, the manufacturing component holds the maximum share of the cell and gene therapy supply chain software market. This trend is unlikely to change in the near future.

Currently, Enterprise Manufacturing System (EMS) Occupies the Largest Share of the Cell and Gene Therapy Supply Chain Software Market

Based on the type of software, the market is segmented into enterprise manufacturing system, laboratory information management system, inventory management system, cell orchestration platform, quality management system, logistics management system and patient management system. At present, enterprise manufacturing system holds the maximum share of the cell and gene therapy supply chain software market. It is worth highlighting that the cell and gene therapy supply chain software market for cell orchestration platforms (COPs) is anticipated to grow at a relatively faster CAGR. This can be attributed to the fact that COPs can be easily integrated with the existing supply chain systems in order to provide end-to-end view of the entire supply chain.

Cloud-Based Software is the Fastest Growing Segment of the Cell and Gene Therapy Supply Chain Software Market During the Forecast Period

Based on the mode of deployment, the market is segmented into on-premises deployment and cloud-based deployment. It is worth highlighting that, at present, on-premises deployment holds a larger share in the cell and gene therapy supply chain software market. However, in the coming years, the market for cloud-based deployment is expected to grow at a relatively faster CAGR.

Software Solutions Used to Manage Clinical Operations Occupies the Largest Share of the Cell and Gene Therapy Supply Chain Software Market

Based on the scale of operation, the market is segmented into clinical and commercial scales. At present, software solutions used to manage clinical operations hold the maximum share of the cell and gene therapy supply chain software market. However, in the coming years, the software solutions used to manage commercial operations are anticipated to grow at a relatively faster pace. This can be attributed to the expected increase in the market approval of cell and gene therapies which are currently in the clinical stages of development.

Pharmaceutical Companies are Likely to Dominate the Cell and Gene Therapy Supply Chain Software Market During the Forecast Period

Based on the type of end-user, the market is segmented into pharmaceutical companies, cell therapy labs, hospitals / medical centers and research institutes / biobanks. Majority of the current cell and gene therapy supply chain software market is captured by the pharmaceutical companies. It is worth highlighting that the cell and gene therapy supply chain software market for cell therapy labs is anticipated to grow at a relatively faster pace.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the world. Majority of the share is expected to be captured by software solution providers based in North America. It is worth highlighting that, over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.

Sample Players in the Cell and Gene Therapy Supply Chain Software Market, Profiled in the Report Include:

Azenta Life Sciences
Biocair
BioLife Solutions
CareDx
Cryoport
Lonza
NMDP BioTherapies
TraceLink
TrakCel
Veeva Systems
Emerson
LabVantage Solutions
Marken
MasterControl
QuickSTAT
Siemens
Stafa Cellular Therapy
Steiner
STEMSOFT Software
TECHNIDATA
Thermo Fisher Scientific

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

Former Chief Business Officer, Mid-sized Company, UK
Chief Clinical Officer, Mid-sized Company, UK
Former Senior Director, Corporate Strategy and Business Development, Very Large Company, US
International Sales and Transfusion Manager, Small Company, France
Former General Manager, Cell Therapy, Very Large Company, US

CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the cell and gene therapy supply chain software market, focusing on key market segments, including process component, type of software, mode of deployment, scale of operation and key geographical regions.
Market Landscape: A comprehensive evaluation of cell and gene therapy supply chain software solutions, considering various parameters, such as type of software, key features, application area, mode of deployment, scale of operation, regulatory guidelines followed and type of end-user. Additionally, it includes a detailed list of developers providing cell and gene therapy supply chain software solutions, along with analysis based on various parameters, such as year of establishment, company size (in terms of employee count), location of headquarters (North America, Europe, Asia-Pacific, and rest of the world) and most active players based on the number of software solutions offered.
Company Competitiveness Analysis: A comprehensive competitive analysis of cell and gene therapy supply chain software solution providers, examining factors, such as developer strength and product portfolio strength.
Company Profiles: In-depth profiles of key cell and gene therapy supply chain software solution providers, focusing on company overviews, software solutions portfolio, financial information, recent developments and an informed future outlook.
Funding and Investment Analysis: A detailed evaluation of the investments made in this domain, encompassing seed funding, venture capital, debt financing, grants / awards, capital raised from IPOs and subsequent offerings.
Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2019, covering acquisitions, platform utilization agreements, service alliances, platform integration agreements, product development agreements, service agreements and other agreements.
Platform Utilization Agreements in Supply Chain Software Solutions Market: An in-depth analysis of the platform utilization agreements inked in this domain since 2019, providing information on the different types of software utilized by end-users in the cell and gene therapy supply chain.
Stakeholder Need Analysis: A qualitative evaluation of the current and future needs of various stakeholders in the cell and gene therapy supply chain, including patients, healthcare providers, collection centers, manufacturers, logistics service providers and regulators. This section provides a summary of the distinct needs of these stakeholders and presents our opinion (drawn from historical and current trends) on the impact of these needs on the supply chain and how the industry is preparing to cater to these needs.
Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting the market growth.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What kind of partnership models are commonly adopted by industry stakeholders?
What are the factors that are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
10% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

1. PREFACE

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Future Estimates
3.2.2. Currency Coverage and Foreign Exchange Rate
3.2.2.1. Major Currencies Affecting the Market
3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
3.2.2.4. Strategies for Mitigating Foreign Exchange Risks
3.2.3. Trade Policies
3.2.3.1. Impact of Trade Barriers on the Market
3.2.3.2. Strategies for Mitigating the Risks associated with Trade Barriers
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

5.1. Chapter Overview
5.2. Overview of Cell Therapies
5.3. Advanced Therapy Medicinal Products (ATMPs)
5.3.1. Difference between Cell / Advanced Therapies and Other Biotechnology Products
5.4. Overview of Cell and Gene Therapy Supply Chain
5.4.1. Software Solutions for Cell and Gene Therapy Supply Chain
5.4.1.1. Enterprise Manufacturing System (EMS)
5.4.1.2. Laboratory Information Management System (LIMS)
5.4.1.3. Inventory Management System (IMS)
5.4.1.4. Quality Management System (QMS)
5.4.1.5. Logistics Management System (LMS)
5.4.1.6. Patient Management System (PMS)
5.4.1.7. Cell Orchestration Platform (COP)
5.4.2. Challenges in Cell and Advanced Therapy Supply Chain
5.5. Recent Developments and Future Outlook

6. MARKET LANDSCAPE

6.1. Chapter Overview
6.2. Cell and Gene Therapy Supply Chain Software: Overall Market Landscape
6.2.1. Analysis by Type of Software
6.2.2. Analysis by Key Features
6.2.3. Analysis by Application Area
6.2.4. Analysis by Mode of Deployment
6.2.5. Analysis by Type of Software and Mode of Deployment
6.2.6. Analysis by Scale of Operation
6.2.7. Analysis by Type of Software and Scale of Operation
6.2.8. Analysis by Regulatory Guidelines Followed
6.2.9. Analysis by Type of End-User
6.2.10. Analysis by Type of Software and End-User
6.3. Cell and Gene Therapy Supply Chain Software: Developer Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Year of Establishment and Company Size
6.3.4. Analysis by Location of Headquarters
6.3.5. Analysis by Number of Software Solutions Offered
6.3.6. Most Active Players: Analysis by Number of Software Solutions Offered

7. COMPANY COMPETITIVENESS ANALYSIS

7.1. Chapter Overview
7.2. Assumptions and Key Parameters
7.3. Methodology
7.4. Company Competitiveness Analysis: Cell and Gene Therapy Supply Chain Software Providers
7.4.1 COP Developers
7.4.2. EMS Developers
7.4.3. IMS Developers
7.4.4. LIMS Developers
7.4.5. LMS Developers
7.4.6. PMS Developers
7.4.7. QMS Developers
7.4.8. TTS Developers

8. COMPANY PROFILES

8.1. Chapter Overview
8.2. Leading Players in Cell and Gene Therapy Supply Chain Software Market
8.2.1. Azenta Life Sciences
8.2.1.1. Company Overview
8.2.1.2. Supply Chain Management Solutions Portfolio
8.2.1.3. Financial Information
8.2.1.4. Recent Developments and Future Outlook
8.2.2. NMDP BioTherapies
8.2.2.1. Company Overview
8.2.2.2. Supply Chain Management Solutions Portfolio
8.2.2.3. Financial Information
8.2.2.4. Recent Developments and Future Outlook
8.2.3. Biocair
8.2.3.1. Company Overview
8.2.3.2. Supply Chain Management Solutions Portfolio
8.2.3.3. Recent Developments and Future Outlook
8.2.4. BioLife Solutions
8.2.4.1. Company Overview
8.2.4.2. Supply Chain Management Solutions Portfolio
8.2.4.3. Financial Information
8.2.4.4. Recent Developments and Future Outlook
8.2.5. CareDx
8.2.5.1. Company Overview
8.2.5.2. Supply Chain Management Solutions Portfolio
8.2.5.3. Financial Information
8.2.5.4. Recent Developments and Future Outlook
8.2.6. Cryoport
8.2.6.1. Company Overview
8.2.6.2. Supply Chain Management Solutions Portfolio
8.2.6.3. Financial Information
8.2.6.4. Recent Developments and Future Outlook
8.2.7. Lonza
8.2.7.1. Company Overview
8.2.7.2. Supply Chain Management Solutions Portfolio
8.2.7.3. Financial Information
8.2.7.4. Recent Developments and Future Outlook
8.2.8. TraceLink
8.2.8.1. Company Overview
8.2.8.2. Supply Chain Management Solutions Portfolio
8.2.8.3. Recent Developments and Future Outlook
8.2.9. TrakCel
8.2.9.1. Company Overview
8.2.9.2. Supply Chain Management Solutions Portfolio
8.2.9.3. Recent Developments and Future Outlook
8.2.10. Veeva Systems
8.2.10.1. Company Overview
8.2.10.2. Supply Chain Management Solutions Portfolio
8.2.10.3. Financial Information
8.2.10.4. Recent Developments and Future Outlook
8.3. Other Leading Players in Cell and Gene Therapy Supply Chain Software Market
8.3.1. Emerson
8.3.1.1. Company Overview
8.3.1.2. Supply Chain Management Solutions Portfolio
8.3.2. LabVantage Solutions
8.3.2.1. Company Overview
8.3.2.2. Supply Chain Management Solutions Portfolio
8.3.3. Marken
8.3.3.1. Company Overview
8.3.3.2. Supply Chain Management Solutions Portfolio
8.3.4. MasterControl
8.3.4.1. Company Overview
8.3.4.2. Supply Chain Management Solutions Portfolio
8.3.5. QuickSTAT
8.3.5.1. Company Overview
8.3.5.2. Supply Chain Management Solutions Portfolio
8.3.6. Siemens
8.3.6.1. Company Overview
8.3.6.2. Supply Chain Management Solutions Portfolio
8.3.7. Stafa Cellular Therapy
8.3.7.1. Company Overview
8.3.7.2. Supply Chain Management Solutions Portfolio
8.3.8. Steiner
8.3.8.1. Company Overview
8.3.8.2. Supply Chain Management Solutions Portfolio
8.3.9. STEMSOFT Software
8.3.9.1. Company Overview
8.3.9.2. Supply Chain Management Solutions Portfolio
8.3.10. TECHNIDATA
8.3.10.1. Company Overview
8.3.10.2. Supply Chain Management Solutions Portfolio
8.3.11. Thermo Fisher Scientific
8.3.11.1. Company Overview
8.3.11.2. Supply Chain Management Solutions Portfolio

9. FUNDING AND INVESTMENT ANALYSIS

9.1. Chapter Overview
9.2. Funding Models
9.3. Cell and Gene Therapy Supply Chain Software: Funding and Investment Analysis
9.3.1. Analysis by Year of Funding
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Type of Funding and Amount Invested
9.3.5. Analysis of Amount Invested by Year and Type of Funding
9.3.6. Analysis by Geography
9.3.7. Most Active Players: Analysis by Number of Instances
9.3.8. Most Active Players: Analysis by Amount Raised
9.3.9. Key Investors: Analysis by Number of Funding Instances
9.3.10. Analysis by Type of Investor
9.4. Concluding Remarks

10. PARTNERSHIPS AND COLLABORATIONS

10.1. Chapter Overview
10.2. Partnership Models
10.3. Cell and Gene Therapy Supply Chain Software: Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Type of Partnership and Company Size
10.3.5. Analysis by Type of Partner
10.3.6. Analysis by Type of Software Involved
10.3.7. Most Active Players: Analysis by Number of Partnerships
10.3.8. Analysis by Geography
10.3.8.1. Local and International Agreements
10.3.8.2. Intracontinental and Intercontinental Agreements

11. PLATFORM UTILIZATION AGREEMENTS IN SUPPLY CHAIN SOFTWARE SOLUTIONS MARKET

11.1. Chapter Overview
11.2. Platform Utilization Agreements in Supply Chain Software Solutions Market: List of Agreements
11.2.1. Analysis by Year of Agreement
11.2.2. Analysis by Type of Partner
11.2.3. Analysis by Type of Software Involved
11.2.4. Analysis by Type of Partner and Type of Software Involved
11.2.5. Analysis of Partners by Geography
11.2.6. Most Active Players: Analysis by Number of Platform Utilization Agreements

12. STAKEHOLDER NEEDS ANALYSIS

12.1. Chapter Overview
12.2. Cell and Gene Therapy Supply Chain: Needs of Different Stakeholders
12.2.1. Comparison of Stakeholder Needs
12.2.2. Conclusion

13. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

13.1. Chapter Overview
13.2. Market Drivers
13.3. Market Restraints
13.4. Market Opportunities
13.5. Market Challenges
13.6. Conclusion

14. GLOBAL CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET

14.1. Chapter Overview
14.2. Assumptions and Methodology
14.3. Global Cell and Gene Therapy Supply Chain Software Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
14.3.1. Scenario Analysis
14.3.1.1. Conservative Scenario
14.3.1.2. Optimistic Scenario
14.4. Key Market Segmentations
14.5. Dynamic Dashboard

15. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET, BY PROCESS COMPONENT

15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Cell and Gene Therapy Supply Chain Software Market: Distribution by Process Component, 2018, 2024 and 2035
15.3.1. Cell and Gene Therapy Supply Chain Software Market for Sample Collection and Processing Component: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
15.3.2. Cell and Gene Therapy Supply Chain Software Market for Manufacturing Component: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
15.3.3. Cell and Gene Therapy Supply Chain Software Market for Logistics Component: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
15.3.4. Cell and Gene Therapy Supply Chain Software Market for Patient Identification and Treatment Follow-Up Component: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
15.4. Data Triangulation and Validation

16. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET, BY TYPE OF SOFTWARE

16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Cell and Gene Therapy Supply Chain Software Market: Distribution by Type of Software, 2018, 2024 and 2035
16.3.1. Cell and Gene Therapy Supply Chain Software Market for EMS: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.2. Cell and Gene Therapy Supply Chain Software Market for LIMS: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.3. Cell and Gene Therapy Supply Chain Software Market for IMS: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.4. Cell and Gene Therapy Supply Chain Software Market for COP: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.5. Cell and Gene Therapy Supply Chain Software Market for QMS: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.6. Cell and Gene Therapy Supply Chain Software Market for LMS: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.7. Cell and Gene Therapy Supply Chain Software Market for PMS: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.4. Data Triangulation and Validation

17. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET, BY MODE OF DEPLOYMENT

17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Cell and Gene Therapy Supply Chain Software Market: Distribution by Mode of Deployment, 2018, 2024 and 2035
17.3.1. Cell and Gene Therapy Supply Chain Software Market for On-premise Deployment: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.3.2. Cell and Gene Therapy Supply Chain Software Market for Cloud-based Deployment: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.4. Data Triangulation and Validation

18. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET, BY SCALE OF OPERATION

18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Cell and Gene Therapy Supply Chain Software Market: Distribution by Scale of Operation, 2018, 2024 and 2035
18.3.1. Cell and Gene Therapy Supply Chain Software Market for Clinical Scale: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.2. Cell and Gene Therapy Supply Chain Software Market for Commercial Scale: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.4. Data Triangulation and Validation

19. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET, BY TYPE OF END-USER

19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Cell and Gene Therapy Supply Chain Software Market: Distribution by Type of End-User, 2018, 2024 and 2035
19.3.1. Cell and Gene Therapy Supply Chain Software Market for Pharmaceutical Companies: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
19.3.2. Cell and Gene Therapy Supply Chain Software Market for Cell Therapy Labs: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
19.3.3. Cell and Gene Therapy Supply Chain Software Market for Hospitals / Medical Centers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
19.3.4. Cell and Gene Therapy Supply Chain Software Market for Research Institutes / Biobanks: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
19.4. Data Triangulation and Validation

20. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET, BY KEY GEOGRAPHICAL REGIONS

20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Cell and Gene Therapy Supply Chain Software Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
20.3.1. Cell and Gene Therapy Supply Chain Software Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.1.1. Cell and Gene Therapy Supply Chain Software Market in the US: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.1.2. Cell and Gene Therapy Supply Chain Software Market in Canada: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.2. Cell and Gene Therapy Supply Chain Software Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.2.1. Cell and Gene Therapy Supply Chain Software Market in the UK: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.2.2. Cell and Gene Therapy Supply Chain Software Market in Germany: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.2.3. Cell and Gene Therapy Supply Chain Software Market in France: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.2.4. Cell and Gene Therapy Supply Chain Software Market in Italy: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.2.5. Cell and Gene Therapy Supply Chain Software Market in Switzerland: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.2.6. Cell and Gene Therapy Supply Chain Software Market in Rest of Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.3. Cell and Gene Therapy Supply Chain Software Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.3.1. Cell and Gene Therapy Supply Chain Software Market in Australia: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.3.2. Cell and Gene Therapy Supply Chain Software Market in China: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.3.3. Cell and Gene Therapy Supply Chain Software Market in Japan: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.3.4. Cell and Gene Therapy Supply Chain Software Market in India: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.3.5. Cell and Gene Therapy Supply Chain Software Market in South Korea: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.3.6. Cell and Gene Therapy Supply Chain Software Market in Rest of Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.4. Cell and Gene Therapy Supply Chain Software Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.4.1. Cell and Gene Therapy Supply Chain Software Market in New Zealand: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.4.2. Cell and Gene Therapy Supply Chain Software Market in Brazil: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.4.3. Cell and Gene Therapy Supply Chain Software Market in Israel: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.3.4.4. Cell and Gene Therapy Supply Chain Software Market in Other Countries: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
20.4. Data Triangulation and Validation

21. CONCLUSION

22. EXECUTIVE INSIGHTS

22.1. Chapter Overview
22.2. TrakCel
22.2.1. Company Snapshot
22.2.2. Interview Transcript: Martin Lamb, (Former Chief Business Officer)
22.3. Cell and Gene Therapy Catapult
22.3.1. Company Snapshot
22.3.2. Interview Transcript: Jacqueline Barry, Chief Clinical Officer
22.4. McKesson
22.4.1. Company Snapshot
22.4.2. Interview Transcript: Divya Iyer, Former Senior Director, Corporate Strategy and Business Development
22.5. Inlog
22.5.1. Company Snapshot
22.5.2. Interview Transcript: David Delay, International Sales and Transfusion Manager
22.6. Thermo Fisher Scientific
22.6.1. Company Snapshot
22.6.2. Interview Transcript: Bryan Poltilove, Former General Manager, Cell and Gene Therapy

23. APPENDIX 1: TABULATED DATA24. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

LIST OF FIGURES

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentations
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: Cell and Gene Therapy Supply Chain Software Market Landscape
Figure 4.2 Executive Summary: Funding and Investment Analysis
Figure 4.3 Executive Summary: Partnerships and Collaborations
Figure 4.4 Executive Summary: Market Forecast and Opportunity Analysis
Figure 5.1 Classification of Advanced Therapy Medicinal Products
Figure 5.2 Difference between Cell / Advanced Therapies and Other Biotechnology Products
Figure 5.3 Components in the Cell and Gene Therapy Supply Chain
Figure 5.4 Software Solutions for Cell and Gene Therapy Supply Chain Management
Figure 5.5 Key Challenges in Cell and Gene Therapy Supply Chain
Figure 6.1 Cell and Gene Therapy Supply Chain Software: Distribution by Type of Software
Figure 6.2 Cell and Gene Therapy Supply Chain Software: Distribution by Key Features
Figure 6.3 Cell and Gene Therapy Supply Chain Software: Distribution by Application Area
Figure 6.4 Cell and Gene Therapy Supply Chain Software: Distribution by Mode of Deployment
Figure 6.5 Cell and Gene Therapy Supply Chain Software: Distribution by Type of Software and Mode of Deployment
Figure 6.6 Cell and Gene Therapy Supply Chain Software: Distribution by Scale of Operation
Figure 6.7 Cell and Gene Therapy Supply Chain Software: Distribution by Type of Software and Scale of Operation
Figure 6.8 Cell and Gene Therapy Supply Chain Software: Distribution by Regulatory Guidelines Followed
Figure 6.9 Cell and Advanced Therapies Supply Chain Management Software: Distribution by Type of End-User
Figure 6.10 Cell and Gene Therapy Supply Chain Software: Distribution by Type of Software and Type of End-User
Figure 6.11 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Year of Establishment
Figure 6.12 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Company Size
Figure 6.13 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Year of Establishment and Company Size
Figure 6.14 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Location of Headquarters (Region)
Figure 6.15 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Location of Headquarters (Country)
Figure 6.16 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Number of Software Solutions Offered
Figure 6.17 Most Active Players: Distribution by Number of Software Solutions Offered
Figure 7.1 Company Competitiveness Analysis: COP Developers
Figure 7.2 Company Competitiveness Analysis: EMS Developers
Figure 7.3 Company Competitiveness Analysis: IMS Developers
Figure 7.4 Company Competitiveness Analysis: LIMS Developers
Figure 7.5 Company Competitiveness Analysis: LMS Developers
Figure 7.6 Company Competitiveness Analysis: PMS Developers
Figure 7.7 Company Competitiveness Analysis: QMS Developers
Figure 7.8 Company Competitiveness Analysis: TTS Developers
Figure 8.1 Azenta Life Sciences: Annual Revenues, FY 2020-FY 2023 (USD Million)
Figure 8.2 NMDP BioTherapies: Annual Revenues, FY 2019-FY 2022 (USD Million)
Figure 8.3 BioLife Solutions: Annual Revenues, FY 2020-FY 2023 (USD Million)
Figure 8.4 CareDx: Annual Revenues, FY 2018-FY 2021 (USD Million)
Figure 8.5 Cryoport: Annual Revenues, FY 2019-9M FY 2023 (USD Million)
Figure 8.6 Lonza: Annual Revenues, FY 2019-FY 2023 (CHF Million)
Figure 8.7 Veeva Systems: Annual Revenues, FY 2020 - FY 2023 (USD Million)
Figure 9.1 Funding and Investment Analysis: Cumulative Year-wise Trend, 2014-2023
Figure 9.2 Funding and Investment Analysis: Distribution by Amount Invested, 2014-2023 (USD Million)
Figure 9.3 Funding and Investment Analysis: Distribution by Type of Funding
Figure 9.4 Funding and Investment Analysis: Distribution by Type of Funding and Amount Invested (USD Million)
Figure 9.5 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Funding, 2014-2023
Figure 9.6 Funding and Investment Analysis: Geographical Distribution of Funding Instances and Amount Invested
Figure 9.7 Funding and Investment Analysis: Geographical Distribution of Funding Instances (Country)
Figure 9.8 Most Active Players: Distribution by Number of Funding Instances
Figure 9.9 Most Active Players: Distribution by Amount Raised (USD Million)
Figure 9.10 Key Investors: Distribution by Number of Funding Instances
Figure 9.11 Funding and Investment Analysis: Distribution by Type of Investor
Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend of Partnerships, 2019-2024
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 10.4 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Figure 10.5 Partnerships and Collaborations: Distribution by Type of Software Involved
Figure 10.6 Partnerships and Collaborations: Distribution by Type of Partner
Figure 10.7 Most Active Players: Distribution by Number of Partnerships
Figure 10.8 Partnerships and Collaborations: Local and International Agreements
Figure 10.9 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 11.1 Platform Utilization Agreements: Cumulative Year-wise Trend of Agreements, 2019-2024
Figure 11.2 Platform Utilization Agreements: Distribution by Type of Partner
Figure 11.3 Platform Utilization Agreements: Distribution by Type of Software Involved
Figure 11.4 Platform Utilization Agreements: Distribution by Type of Partner and Type of Software Involved
Figure 11.5 Platform Utilization Agreements: Distribution of Partners by Geography
Figure 11.6 Most active Players: Distribution by Number of Platform Utilization Agreements
Figure 12.1 Cell and Gene Therapy Supply Chain: Stakeholder Needs
Figure 12.2 Relative Importance of Stakeholders Needs
Figure 13.1 Cell and Gene Therapy Supply Chain Software: Market Drivers
Figure 13.2 Cell and Gene Therapy Supply Chain Software: Market Restraints
Figure 13.3 Cell and Gene Therapy Supply Chain Software: Market Opportunities
Figure 13.4 Cell and Gene Therapy Supply Chain Software: Market Challenges
Figure 14.1 Global Cell and Gene Therapy Supply Chain Software Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 14.2 Global Cell and Gene Therapy Supply Chain Software Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Million)
Figure 14.3 Global Cell and Gene Therapy Supply Chain Software Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Million)
Figure 15.1 Cell and Gene Therapy Supply Chain Software Market: Distribution by Process Component, 2018, 2024 and 2035 (USD Million)
Figure 15.2 Cell and Gene Therapy Supply Chain Software Market for Sample Collection and Processing Component, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 15.3 Cell and Gene Therapy Supply Chain Software Market for Manufacturing Component, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 15.4 Cell and Gene Therapy Supply Chain Software Market for Logistics Component, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 15.5 Cell and Gene Therapy Supply Chain Software Market for Patient Identification and Treatment Follow-Up Component, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 16.1 Cell and Gene Therapy Supply Chain Software Market: Distribution by Type of Software Solution, 2018, 2024 and 2035 (USD Million)
Figure 16.2 Cell and Gene Therapy Supply Chain Software Market for EMS, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 16.3 Cell and Gene Therapy Supply Chain Software Market for LIMS, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 16.4 Cell and Gene Therapy Supply Chain Software Market for IMS, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 16.5 Cell and Gene Therapy Supply Chain Software Market for COP, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 16.6 Cell and Gene Therapy Supply Chain Software Market for QMS, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 16.7 Cell and Gene Therapy Supply Chain Software Market for LMS, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 16.8 Cell and Gene Therapy Supply Chain Software Market for PMS, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 17.1 Cell and Gene Therapy Supply Chain Software Market: Distribution by Mode of Deployment, 2018, 2024 and 2035 (USD Million)
Figure 17.2 Cell and Gene Therapy Supply Chain Software Market for On-premise Deployment, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 17.3 Cell and Gene Therapy Supply Chain Software Market for Cloud-based Deployment, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 18.1 Cell and Gene Therapy Supply Chain Software Market: Distribution by Scale of Operation, 2018, 2024 and 2035 (USD Million)
Figure 18.2 Cell and Gene Therapy Supply Chain Software Market for Clinical Scale, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 18.3 Cell and Gene Therapy Supply Chain Management Software Market for Commercial Scale, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 19.1 Cell and Gene Therapy Supply Chain Software Market: Distribution by Type of End-User, 2018, 2024 and 2035 (USD Million)
Figure 19.2 Cell and Gene Therapy Supply Chain Software Market for Pharmaceutical Companies, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 19.3 Cell and Gene Therapy Supply Chain Software Market for Cell Therapy Labs, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 19.4 Cell and Gene Therapy Supply Chain Software Market for Hospitals / Medical Centers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 19.5 Cell and Gene Therapy Supply Chain Software Market for Research Institutes / Biobanks, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 20.1 Cell and Gene Therapy Supply Chain Software Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035 (USD Million)
Figure 20.2 Cell and Gene Therapy Supply Chain Software Market in North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 20.3 Cell and Gene Therapy Supply Chain Software Market in the US, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 20.4 Cell and Gene Therapy Supply Chain Software Market in Canada, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 20.5 Cell and Gene Therapy Supply Chain Software Market in Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 20.6 Cell and Gene Therapy Supply Chain Management Software Market in the UK, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 20.7 Cell and Gene Therapy Supply Chain Management Software Market in Germany, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 20.8 Cell and Gene Therapy Supply Chain Software Market in France, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 20.9 Cell and Gene Therapy Supply Chain Software Market in Italy, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 20.10 Cell and Gene Therapy Supply Chain Software Market in Switzerland, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 20.11 Cell and Gene Therapy Supply Chain Software Market in Rest of Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 20.12 Cell and Gene Therapy Supply Chain Software Market in Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 20.13 Cell and Gene Therapy Supply Chain Software Market in Australia, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 20.14 Cell and Gene Therapy Supply Chain Software Market in China, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 20.15 Cell and Gene Therapy Supply Chain Software Market in Japan, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 20.16 Cell and Gene Therapy Supply Chain Software Market in India, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 20.17 Cell and Gene Therapy Supply Chain Software Market in South Korea, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 20.18 Cell and Gene Therapy Supply Chain Software Market in Rest of Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 20.19 Cell and Gene Therapy Supply Chain Software Market in Rest of the World, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 20.20 Cell and Gene Therapy Supply Chain Software Market in New Zealand, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 20.21 Cell and Gene Therapy Supply Chain Software Market in Brazil, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 20.22 Cell and Gene Therapy Supply Chain Software Market in Israel, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 20.23 Cell and Gene Therapy Supply Chain Software Market in Other Countries, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
Figure 21.1 Conclusion: Cell and Gene Therapy Supply Chain Software Market Landscape
Figure 21.2 Conclusion: Funding and Investment Analysis
Figure 21.3 Conclusion: Partnerships and Collaborations
Figure 21.4 Conclusion: Market Forecast and Opportunity Analysis

LIST OF TABLES

Table 5.1 Therapeutic Applications of Cell Therapies
Table 6.1 Cell and Gene Therapy Supply Chain Software: Information on Type of Software and Key Features Offered
Table 6.2 Cell and Gene Therapy Supply Chain Software: Information on Application Area
Table 6.3 Cell and Gene Therapy Supply Chain Software: Information on Mode of Deployment and Scale of Operation
Table 6.4 Cell and Gene Therapy Supply Chain Software: Information on Regulatory Guidelines Followed
Table 6.5 Cell and Gene Therapy Supply Chain Software: Information on Type of End-User
Table 6.6 List of Cell and Gene Therapy Supply Chain Software Developers
Table 8.1 Cell and Gene Therapy Supply Chain Software: List of Companies Profiled
Table 8.2 Cell and Gene Therapy Supply Chain Software: List of Other Leading Players
Table 8.3 Azenta Life Sciences: Company Overview
Table 8.4 Azenta Life Sciences: Supply Chain Management Solutions Portfolio
Table 8.5 Azenta Life Sciences: Recent Developments and Future Outlook
Table 8.6 NMDP BioTherapies: Company Overview
Table 8.7 NMDP BioTherapies: Supply Chain Management Solutions Portfolio
Table 8.8 NMDP BioTherapies: Recent Developments and Future Outlook
Table 8.9 Biocair: Company Overview
Table 8.10 Biocair: Supply Chain Management Solutions Portfolio
Table 8.11 Biocair: Recent Developments and Future Outlook
Table 8.12 BioLife Solutions: Company Overview
Table 8.13 BioLife Solutions: Supply Chain Management Solutions Portfolio
Table 8.14 BioLife Solutions: Recent Developments and Future Outlook
Table 8.15 CareDx: Company Overview
Table 8.16 CareDx: Supply Chain Management Solutions Portfolio
Table 8.17 CareDX: Recent Developments and Future Outlook
Table 8.18 Cryoport: Company Overview
Table 8.19 Cryoport: Supply Chain Management Solutions Portfolio
Table 8.20 Cryoport: Recent Developments and Future Outlook
Table 8.21 Lonza: Company Overview
Table 8.22 Lonza: Supply Chain Management Solutions Portfolio
Table 8.23 Lonza: Recent Developments and Future Outlook
Table 8.24 TraceLink: Company Overview
Table 8.25 TraceLink: Supply Chain Management Solutions Portfolio
Table 8.26 TraceLink: Recent Developments and Future Outlook
Table 8.27 TrakCel: Company Overview
Table 8.28 TrakCel: Supply Chain Management Solutions Portfolio
Table 8.29 TrakCel: Recent Developments and Future Outlook
Table 8.30 Veeva Systems: Company Overview
Table 8.31 Veeva Systems: Supply Chain Management Solutions Portfolio
Table 8.32 Veeva Systems: Recent Developments and Future Outlook
Table 8.33 Emerson: Company Overview
Table 8.34 Emerson: Supply Chain Management Solutions Portfolio
Table 8.35 LabVantage Solutions: Company Overview
Table 8.36 LabVantage Solutions: Supply Chain Management Solutions Portfolio
Table 8.37 Marken: Company Overview
Table 8.38 Marken: Supply Chain Management Solutions Portfolio
Table 8.39 MasterControl: Company Overview
Table 8.40 MasterControl: Supply Chain Management Solutions Portfolio
Table 8.41 QuickSTAT: Company Overview
Table 8.42 QuickSTAT: Supply Chain Management Solutions Portfolio
Table 8.43 Siemens: Company Overview
Table 8.44 Siemens: Supply Chain Management Solutions Portfolio
Table 8.45 Stafa Cellular Therapy: Company Overview
Table 8.46 Stafa Cellular Therapy: Supply Chain Management Solutions Portfolio
Table 8.47 Steiner: Company Overview
Table 8.48 Steiner: Supply Chain Management Solutions Portfolio
Table 8.49 STEMSOFT Software: Company Overview
Table 8.50 STEMSOFT Software: Supply Chain Management Solutions Portfolio
Table 8.51 TECHNIDATA: Company Overview
Table 8.52 TECHNIDATA: Supply Chain Management Solutions Portfolio
Table 8.53 Thermo Fisher Scientific: Company Overview
Table 8.54 Thermo Fisher Scientific: Supply Chain Management Solutions Portfolio
Table 9.1 Cell and Gene Therapy Supply Chain Software: List of Funding and Investments, 2014-2023
Table 10.1 Cell and Gene Therapy Supply Chain Software: List of Partnerships and Collaborations, 2019-2024
Table 11.1 Cell and Gene Therapy Supply Chain Software: List of Platform Utilization Agreements, 2019-2024
Table 22.1 TrakCel: Company Snapshot
Table 22.2 Cell and Gene Therapy Catapult: Company Snapshot
Table 22.3 McKesson: Company Snapshot
Table 22.4 Inlog: Company Snapshot
Table 22.5 Thermo Fisher Scientific: Company Snapshot
Table 23.1 Cell and Gene Therapy Supply Chain Software: Distribution by Type of Software
Table 23.2 Cell and Gene Therapy Supply Chain Software: Distribution by Key Features
Table 23.3 Cell and Gene Therapy Supply Chain Software: Distribution by Application Area
Table 23.4 Cell and Gene Therapy Supply Chain Software: Distribution by Mode of Deployment
Table 23.5 Cell and Gene Therapy Supply Chain Software: Distribution by Type of Software and Mode of Deployment
Table 23.6 Cell and Gene Therapy Supply Chain Software: Distribution by Scale of Operation
Table 23.7 Cell and Gene Therapy Supply Chain Software: Distribution by Type of Software and Scale of Operation
Table 23.8 Cell and Gene Therapy Supply Chain Software: Distribution by Regulatory Guidelines Followed
Table 23.9 Cell and Advanced Therapies Supply Chain Management Software: Distribution by Type of End-User
Table 23.10 Cell and Gene Therapy Supply Chain Software: Distribution by Type of Software and Type of End-User
Table 23.11 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Year of Establishment
Table 23.12 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Company Size
Table 23.13 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Year of Establishment and Company Size
Table 23.14 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Location of Headquarters (Region)
Table 23.15 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Location of Headquarters (Country)
Table 23.16 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Number of Software Solutions Offered
Table 23.17 Most Active Players: Distribution by Number of Software Solutions Offered
Table 23.18 Azenta Life Sciences: Annual Revenues, FY 2020-FY 2023 (USD Million)
Table 23.19 NMDP BioTherapies: Annual Revenues, FY 2019 - FY 2022 (USD Million)
Table 23.20 BioLife Solutions: Annual Revenues, FY 2020 - FY 2023 (USD Million)
Table 23.21 CareDx: Annual Revenues, FY 2018 - FY 2021 (USD Million)
Table 23.22 Cryoport: Annual Revenues, FY 2019 - 9M FY 2023 (USD Million)
Table 23.23 Lonza: Annual Revenues, FY 2019 - FY 2023 (CHF Million)
Table 23.24 Veeva Systems: Annual Revenues, FY 2020 - FY 2023 (USD Million)
Table 23.25 Funding and Investment Analysis: Cumulative Year-wise Trend, 2014-2023
Table 23.26 Funding and Investment Analysis: Distribution by Amount Invested, 2014-2023 (USD Million)
Table 23.27 Funding and Investment Analysis: Distribution by Type of Funding, 2014-2023
Table 23.28 Funding and Investment Analysis: Distribution by Type of Funding and Amount Invested (USD Million)
Table 23.29 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Funding, 2014-2023
Table 23.30 Funding and Investment Analysis: Geographical Distribution of Funding Instances and Amount Invested
Table 23.31 Funding and Investment Analysis: Geographical Distribution of Funding Instances (Country)
Table 23.32 Most Active Players: Distribution by Number of Funding Instances
Table 23.33 Most Active Players: Distribution by Amount Raised (USD Million)
Table 23.34 Key Investors: Distribution by Number of Funding Instances
Table 23.35 Funding and Investment Analysis: Distribution by Type of Investor
Table 23.36 Partnerships and Collaborations: Cumulative Year-wise Trend of Partnerships, 2019-2024
Table 23.37 Partnerships and Collaborations: Distribution by Type of Partnership
Table 23.38 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 23.39 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Table 23.40 Partnerships and Collaborations: Distribution by Type of Software Involved
Table 23.41 Partnerships and Collaborations: Distribution by Type of Partner
Table 23.42 Most Active Players: Distribution by Number of Partnerships
Table 23.43 Partnerships and Collaborations: Local and International Agreements
Table 23.44 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 23.45 Platform Utilization Agreements: Cumulative Year-wise Trend of Agreements, 2019-2024
Table 23.46 Platform Utilization Agreements: Distribution by Type of Partner
Table 23.47 Platform Utilization Agreements: Distribution by Type of Software Involved
Table 23.48 Platform Utilization Agreements: Distribution by Type of Partner and Type of Software Involved
Table 23.49 Platform Utilization Agreements: Distribution of Partners by Geography
Table 23.50 Most active Players: Distribution by Number of Platform Utilization Agreements
Table 23.51 Global Cell and Gene Therapy Supply Chain Software Market, Historical Trends (2018-2023) (USD Million)
Table 23.52 Global Cell and Gene Therapy Supply Chain Software Market, Forecasted Estimates (2024-2035) Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.53 Cell and Gene Therapy Supply Chain Software Market: Distribution by Process Component, 2018, 2024 and 2035 (USD Million)
Table 23.54 Cell and Gene Therapy Supply Chain Software Market for Sample Collection and Processing Component: Historical Trends (2018-2023) (USD Million)
Table 23.55 Cell and Gene Therapy Supply Chain Software Market for Sample Collection and Processing Component: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.56 Cell and Gene Therapy Supply Chain Software Market for Manufacturing Component: Historical Trends (2018-2023) (USD Million)
Table 23.57 Cell and Gene Therapy Supply Chain Software Market for Manufacturing Component: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.58 Cell and Gene Therapy Supply Chain Software Market for Logistics Component: Historical Trends (2018-2023) (USD Million)
Table 23.59 Cell and Gene Therapy Supply Chain Software Market for Logistics Component: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.60 Cell and Gene Therapy Supply Chain Software Market for Patient Identification and Treatment Follow-Up Component: Historical Trends (2018-2023) (USD Million)
Table 23.61 Cell and Gene Therapy Supply Chain Software Market for Patient Identification and Treatment Follow-Up Component: Forecasted Estimates (2024-2035), Conservative,Base and Optimistic Scenarios (USD Million)
Table 23.62 Cell and Gene Therapy Supply Chain Software Market: Distribution by Type of Software, 2018, 2024 and 2035 (USD Million)
Table 23.63 Cell and Gene Therapy Supply Chain Software Market for EMS: Historical Trends (2018-2023) (USD Million)
Table 23.64 Cell and Gene Therapy Supply Chain Software Market for EMS: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.65 Cell and Gene Therapy Supply Chain Software Market for LIMS: Historical Trends (2018-2023) (USD Million)
Table 23.66 Cell and Gene Therapy Supply Chain Software Market for LIMS: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.67 Cell and Gene Therapy Supply Chain Software Market for IMS: Historical Trends (2018-2023) (USD Million)
Table 23.68 Cell and Gene Therapy Supply Chain Software Market for IMS: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.69 Cell and Gene Therapy Supply Chain Software Market for COP: Historical Trends (2018-2023) (USD Million)
Table 23.70 Cell and Gene Therapy Supply Chain Software Market for COP: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.71 Cell and Gene Therapy Supply Chain Software Market for QMS: Historical Trends (2018-2023) (USD Million)
Table 23.72 Cell and Gene Therapy Supply Chain Software Market for QMS: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.73 Cell and Gene Therapy Supply Chain Software Market for LMS: Historical Trends (2018-2023) (USD Million)
Table 23.74 Cell and Gene Therapy Supply Chain Software Market for LMS: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.75 Cell and Gene Therapy Supply Chain Software Market for PMS: Historical Trends (2018-2023) (USD Million)
Table 23.76 Cell and Gene Therapy Supply Chain Software Market for PMS: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.77 Cell and Gene Therapy Supply Chain Software Market: Distribution by Mode of Deployment, 2018, 2024 and 2035 (USD Million)
Table 23.78 Cell and Gene Therapy Supply Chain Software Market for On-premise Deployment: Historical Trends (2018-2023) (USD Million)
Table 23.79 Cell and Gene Therapy Supply Chain Software Market for On-premise Deployment: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USDMillion)
Table 23.80 Cell and Gene Therapy Supply Chain Software Market for Cloud-based Deployment: Historical Trends (2018-2023) (USD Million)
Table 23.81 Cell and Gene Therapy Supply Chain Software Market for Cloud-based Deployment: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.82 Cell and Gene Therapy Supply Chain Software Market: Distribution by Scale of Operation, 2018, 2024 and 2035 (USD Million)
Table 23.83 Cell and Gene Therapy Supply Chain Software Market for Clinical Scale: Historical Trends (2018-2023) (USD Million)
Table 23.84 Cell and Gene Therapy Supply Chain Software Market for Clinical Scale: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.85 Cell and Gene Therapy Supply Chain Management Software Market for Commercial Scale: Historical Trends (2018-2023) (USD Million)
Table 23.86 Cell and Gene Therapy Supply Chain Management Software Market for Commercial Scale: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.87 Cell and Gene Therapy Supply Chain Software Market: Distribution by Type of End-User, 2018, 2024 and 2035 (USD Million)
Table 23.88 Cell and Gene Therapy Supply Chain Software Market for Pharmaceutical Companies: Historical Trends (2018-2023) (USD Million)
Table 23.89 Cell and Gene Therapy Supply Chain Software Market for Pharmaceutical Companies: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.90 Cell and Gene Therapy Supply Chain Software Market for Cell Therapy Labs: Historical Trends (2018-2023) (USD Million)
Table 23.91 Cell and Gene Therapy Supply Chain Software Market for Cell Therapy Labs: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.92 Cell and Gene Therapy Supply Chain Software Market for Hospitals / Medical Centers: Historical Trends (2018-2023) (USD Million)
Table 23.93 Cell and Gene Therapy Supply Chain Software Market for Hospitals / Medical Centers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.94 Cell and Gene Therapy Supply Chain Software Market for Research Institutes / Biobanks: Historical Trends (2018-2023) (USD Million)
Table 23.95 Cell and Gene Therapy Supply Chain Software Market for Research Institutes / Biobanks: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.96 Cell and Gene Therapy Supply Chain Software Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035 (USD Million)
Table 23.97 Cell and Gene Therapy Supply Chain Software Market in North America: Historical Trends (2018-2023) (USD Million)
Table 23.98 Cell and Gene Therapy Supply Chain Software Market in North America: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.99 Cell and Gene Therapy Supply Chain Software Market in the US: Historical Trends (2018-2023) (USD Million)
Table 23.100 Cell and Gene Therapy Supply Chain Software Market in the US: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.101 Cell and Gene Therapy Supply Chain Software Market in Canada: Historical Trends (2018-2023) (USD Million)
Table 23.102 Cell and Gene Therapy Supply Chain Software Market in Canada: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.103 Cell and Gene Therapy Supply Chain Software Market in Europe: Historical Trends (2018-2023) (USD Million)
Table 23.104 Cell and Gene Therapy Supply Chain Software Market in Europe: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.105 Cell and Gene Therapy Supply Chain Management Software Market in the UK: Historical Trends (2018-2023) (USD Million)
Table 23.106 Cell and Gene Therapy Supply Chain Management Software Market in the UK: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.107 Cell and Gene Therapy Supply Chain Management Software Market in Germany: Historical Trends (2018-2023) (USD Million)
Table 23.108 Cell and Gene Therapy Supply Chain Management Software Market in Germany: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.109 Cell and Gene Therapy Supply Chain Software Market in France: Historical Trends (2018-2023) (USD Million)
Table 23.110 Cell and Gene Therapy Supply Chain Software Market in France: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.111 Cell and Gene Therapy Supply Chain Software Market in Italy: Historical Trends (2018-2023) (USD Million)
Table 23.112 Cell and Gene Therapy Supply Chain Software Market in Italy: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.113 Cell and Gene Therapy Supply Chain Software Market in Switzerland: Historical Trends (2018-2023) (USD Million)
Table 23.114 Cell and Gene Therapy Supply Chain Software Market in Switzerland: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.115 Cell and Gene Therapy Supply Chain Software Market in Rest of Europe: Historical Trends (2018-2023) (USD Million)
Table 23.116 Cell and Gene Therapy Supply Chain Software Market in Rest of Europe: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.117 Cell and Gene Therapy Supply Chain Software Market in Asia-Pacific: Historical Trends (2018-2023) (USD Million)
Table 23.118 Cell and Gene Therapy Supply Chain Software Market in Asia-Pacific: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.119 Cell and Gene Therapy Supply Chain Software Market in Australia: Historical Trends (2018-2023) (USD Million)
Table 23.120 Cell and Gene Therapy Supply Chain Software Market in Australia: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.121 Cell and Gene Therapy Supply Chain Software Market in China: Historical Trends (2018-2023) (USD Million)
Table 23.122 Cell and Gene Therapy Supply Chain Software Market in China: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.123 Cell and Gene Therapy Supply Chain Software Market in Japan: Historical Trends (2018-2023) (USD Million)
Table 23.124 Cell and Gene Therapy Supply Chain Software Market in Japan: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.125 Cell and Gene Therapy Supply Chain Software Market in India: Historical Trends (2018-2023) (USD Million)
Table 23.126 Cell and Gene Therapy Supply Chain Software Market in India: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.127 Cell and Gene Therapy Supply Chain Software Market in South Korea: Historical Trends (2018-2023) (USD Million)
Table 23.128 Cell and Gene Therapy Supply Chain Software Market in South Korea: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.129 Cell and Gene Therapy Supply Chain Software Market in Rest of Asia-Pacific: Historical Trends (2018-2023) (USD Million)
Table 23.130 Cell and Gene Therapy Supply Chain Software Market in Rest of Asia-Pacific: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.131 Cell and Gene Therapy Supply Chain Software Market in Rest of the World: Historical Trends (2018-2023) (USD Million)
Table 23.132 Cell and Gene Therapy Supply Chain Software Market in Rest of the World: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.133 Cell and Gene Therapy Supply Chain Software Market in New Zealand: Historical Trends (2018-2023) (USD Million)
Table 23.134 Cell and Gene Therapy Supply Chain Software Market in New Zealand: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.135 Cell and Gene Therapy Supply Chain Software Market in Brazil: Historical Trends (2018-2023) (USD Million)
Table 23.136 Cell and Gene Therapy Supply Chain Software Market in Brazil: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.137 Cell and Gene Therapy Supply Chain Software Market in Israel: Historical Trends (2018-2023) (USD Million)
Table 23.138 Cell and Gene Therapy Supply Chain Software Market in Israel: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.139 Cell and Gene Therapy Supply Chain Software Market in Other Countries: Historical Trends (2018-2023) (USD Million)
Table 23.140 Cell and Gene Therapy Supply Chain Software Market in Other Countries: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Azenta Life Sciences
Biocair
BioLife Solutions
CareDx
Cryoport
Lonza
NMDP BioTherapies
TraceLink
TrakCel
Veeva Systems
Emerson
LabVantage Solutions
Marken
MasterControl
QuickSTAT
Siemens
Stafa Cellular Therapy
Steiner
STEMSOFT Software
TECHNIDATA
Thermo Fisher Scientific

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a single user license, allowing one user access to the product.	€4284EUR$4,799USD£3,748GBP
SITE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€6248EUR$6,999USD£5,467GBP
ENTERPRISE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is an enterprise license, allowing all employees within your organization access to the product.	€16068EUR$17,999USD£14,058GBP